Cargando…
Antineoplastic treatment class modulates COVID-19 mRNA-BNT162b2 vaccine immunogenicity in cancer patients: a secondary analysis of the prospective Vax-On study
BACKGROUND: Preliminary analysis from the Vax-On study did not find a correlation between cancer treatment type and antibody response to COVID-19 vaccination. We carried out a secondary subgroup analysis to verify the effects of comprehensive cancer treatment classification on vaccine immunogenicity...
Autores principales: | Ruggeri, E.M., Nelli, F., Fabbri, A., Onorato, A., Giannarelli, D., Giron Berrios, J.R., Virtuoso, A., Marrucci, E., Mazzotta, M., Schirripa, M., Panichi, V., Pessina, G., Signorelli, C., Chilelli, M.G., Primi, F., Natoni, F., Fazio, S., Silvestri, M.A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8626231/ https://www.ncbi.nlm.nih.gov/pubmed/34942438 http://dx.doi.org/10.1016/j.esmoop.2021.100350 |
Ejemplares similares
-
Immunogenicity and early clinical outcome after two or three doses of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: results from the prospective observational Vax-On-Third study
por: Nelli, F., et al.
Publicado: (2022) -
Six month immunogenicity of COVID-19 mRNA-BNT162b2 vaccine in actively treated cancer patients: updated results of the Vax-On study
por: Nelli, F., et al.
Publicado: (2022) -
Effects of active cancer treatment on safety and immunogenicity of COVID-19 mRNA-BNT162b2 vaccine: preliminary results from the prospective observational Vax-On study
por: Nelli, F., et al.
Publicado: (2022) -
Peripheral lymphocyte subset counts predict antibody response after SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients: Results from the Vax-On-Profile study
por: Nelli, Fabrizio, et al.
Publicado: (2022) -
Effects of Antibody Response after Booster Vaccination on SARS-CoV-2 Breakthrough Infections and Disease Outcomes in Advanced Cancer Patients: A Prospective Analysis of the Vax-on-Third Study
por: Nelli, Fabrizio, et al.
Publicado: (2023)